18 news items
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
AAPL
BLDR
GOOG
8 May 24
being raised about its ability to remain independent of political influence. The Fed’s Chairman, Jerome Powell, is under intense
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
MRK
1 May 24
after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
MRK
29 Apr 24
years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive
Merck Announces First-Quarter 2024 Financial Results
MRK
25 Apr 24
the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
MRK
19 Apr 24
aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver
t92m2jvryutz7jia5cx817rk
MRK
4 Apr 24
intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite
6kgjnr09ijry5xmevy3idrwmz9sw dre4huydi0utzkddlla
MRK
28 Mar 24
), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without
wxfa3644k5 b8r3exj7n
MRK
26 Mar 24
to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company
c2p9y6x18zmq5wdete 88rw8z7edtw
MRK
15 Mar 24
-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications
d3iuzuqrncvbcn5s1ub 3qc9cnr4vk9a8vzucaiffz
MRK
13 Mar 24
, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive
ftww8yy8pdmsoyo93klgv78281lgrc3o
HARP
MRK
11 Mar 24
the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today
b3a0tacx5xkf9hygal7lfw9x7ddebfjw 44wz
GILD
MRK
6 Mar 24
research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions
bz7hv2xp2nww 484lsejn1atvcdo
MRK
5 Mar 24
the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we
r1z4husd3p6etngo20xk2mdimtmfcnwidm4447qoxpwr21pnltlx2eshb8
MRK
4 Mar 24
years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive
x4pzkr2euk9o8avk9hryc9olzuyfhp fy6g3eai7fod
MRK
27 Feb 24
to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company
6qwu1tph4aspx0ln9ceh8x9ywac6cbfgz8u45qyuxiuoodnrwhz
MRK
23 Feb 24
disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may
6vh7r6soeq5hbqa7pr7n03xa51nxp3ggfnph333uf183yk777 n8gcvx9ol
MRK
12 Feb 24
of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we
633 man24smvy08klzittwbkwz7
MRK
8 Feb 24
-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance
- Prev
- 1
- Next